KENDALL PARK, N.J., June 28 /PRNewswire/ -- EvoLife Laboratories was present at the annual Multinational Association of Supportive Care in Cancer (MASCC) 2010, Vancouver and utilized the opportunity to engage with oncologists and caregivers to not only advocate, but educate them about quality of life altering supportive cancer care. EvoLife Laboratories, a world leader in the development of innovative products for skin, oral, nail, hair, hygiene care specifically designed for cancer patients undergoing chemotherapy and radiotherapy treatments, successfully launched its products in the USA in 2010.
EvoLife's Scientific Advances towards Supportive Cancer Care
At the 4th Annual Mucositis Research Workshop, leading dentist-scientist and Chair of the Mucositis Study Group, Dr. Rajesh Lalla, D.D.S., Ph.D., C.C.R.P., presented results of his study on the Evomucy Mouth Rinse Spray. The study aimed at examining the safety and tolerability of the spray in chemotherapy-induced oral mucositis. Study completion is required to make definitive conclusions, though current results show that Evomucy Spray appears to be safe and well-tolerated in chemotherapy patients.
EvoLife's commitment to improving the overall quality of life of patients through an innovative product line ensures and increases their ability to undergo and stay on the treatment regimen. They are the first and only products of their kind that are effective, uniquely designed with the needs of cancer patients in mind and well tested - "The Neurogenic Component of Cutaneous Toxicities Induced by Chemotherapy – New Solutions. J. F. Chanez. European Oncology."
EvoLife gears up for expansion
EvoLife Laboratories continues to build its global network with the recent launch of its products in North America, Europe, and Asia. The only oncocosmetic company in the US is also planning to increase its presence at various sales outlets and collaborate towards building local partnerships with distributors across key regions.
SOURCE EvoLife Laboratories